Small RCT 103 severe condition patients, 52 treated with convalescent plasma, showing improved viral clearance but no statistically significant improvements in mortality or clinical improvement. ChiCTR2000029757.
Li et al., 6/3/2020, Randomized Controlled Trial, China, Asia, peer-reviewed, 34 authors.
risk of death, 34.6% lower, RR 0.65, p = 0.30, treatment 8 of 51 (15.7%), control 12 of 50 (24.0%), odds ratio converted to relative risk, 28 days.
risk of no improvement, 15.3% lower, RR 0.85, p = 0.37, treatment 25 of 52 (48.1%), control 29 of 51 (56.9%), odds ratio converted to relative risk, 28 days.
risk of no virological cure, 76.4% lower, RR 0.24, p < 0.001, treatment 4 of 26 (15.4%), control 15 of 23 (65.2%), odds ratio converted to relative risk.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.